Mollugin

Mollugin is an orally active and potent NF-κB inhibitor. Mollugin induces S-phase arrest of HepG2 cells, and increased intracellular reactive oxygen species (ROS) levels. Mollugin induces DNA damage in HepG2 cells, as well as an increase in the expression of p-H2AX. Mollugin shows anti-cancer effect by inhibiting TNF-α-induced NF-κB activation. Mollugin enhances the osteogenic action of BMP-2 (bone morphogenetic protein 2) via the p38-Smad signaling pathway[1][2][3].

Product Specifications

CAS Number

[55481-88-4]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; c-Myc; JAK; NF-κB; Reactive Oxygen Species (ROS) ; VEGFR

Type

Natural Products

Related Pathways

Apoptosis; Epigenetics; Immunology/Inflammation; JAK/STAT Signaling; Metabolic Enzyme/Protease; NF-κB; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/mollugin.html

Purity

99.79

Solubility

DMSO : 33.33 mg/mL (ultrasonic)

Smiles

O=C(C1=C(C=CC(C)(C)O2)C2=C3C=CC=CC3=C1O)OC

Molecular Formula

C17H16O4

Molecular Weight

284.31

Precautions

H302, H315, H319, H335

References & Citations

[1]Wang Z, et al. Mollugin Has an Anti-Cancer Therapeutic Effect by Inhibiting TNF-α-Induced NF-κB Activation. Int J Mol Sci. 2017 Jul 26;18 (8) .|[2]Moon SH, et al. Mollugin enhances the osteogenic action of BMP-2 via the p38-Smad signaling pathway. Arch Pharm Res. 2017 Nov;40 (11) :1328-1335.|[3]Ke XG, Xiong YY, Yu B, et al. Mollugin induced oxidative DNA damage via up-regulating ROS that caused cell cycle arrest in hepatoma cells. Chem Biol Interact. 2022;353:109805.